Drug Trial Radar · NCT04185441
Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
295
Actual
Start
Mar 14, 2021
Primary completion
Oct 10, 2023
Study completion Jul 5, 2024
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Tanzânia association in adults with erectile dysfunction associated with Benign Prostatic Hyperplasia.
Conditions
- Erectile Dysfunction
- Benign Prostatic Hyperplasia
Interventions
Tanzânia associationDrug
Tanzânia association capsule
Omnic OcasDrug
Tamsulosin 0,4 mg
Omnic Ocas placeboOther
Tamsulosin placebo
Tanzânia association placeboOther
EMS association placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in erectile function questionnaire.Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Allergisa
Campinas, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.